gemcitabine has been researched along with Carcinoma, Ductal, Breast in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 20 (64.52) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Arjyal, L; Khan, AM; Shamaileh, L; Simon, M | 1 |
| Jhaj, G; Jhaj, R; Shrier, EM | 1 |
| Balmaña, J; Cedrés, S; Cruz, C; Felip, E; Llop-Guevara, A; Mancuso, F; Martinez de Castro, A; Martinez-Marti, A; Miquel, JM; Navarro, A; Nuciforo, P; Pardo, N; Remon, J; Sansano, I; Serra, V; Vivancos, A; Zeron-Medina, J | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Jinno, H; Kitagawa, Y; Kitasato, K; Murai, S; Nakadai, J; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T | 1 |
| Di, G; Hu, X; Hu, Z; Liu, G; Liu, Y; Shao, Z; Wang, B; Wang, L; Wang, Z; Wu, J; Yang, W; Zhang, J | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Cao, ZG; Chen, DN; Chen, L; Hu, X; Li, S; Ling, H; Qiao, F; Shao, ZM; Song, CG; Xia, C; Yao, L; Ye, FG | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Li, H; Li, J; Sun, W; Wang, X; Wei, H; Yi, Z | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Baker, MK; Branch, KD; Gluck, S; Goldsberry, GT; Montero, AJ; Talebi, TN; Zhu, Y | 1 |
| Bult, P; van Herpen, CM; van Laarhoven, HW; Wesseling, P; Willemsen, AE | 1 |
| Halim, A; Wahba, H | 1 |
| Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S | 1 |
| Bergerat, JP; Delpeuch, A; Leveque, D; Rob, L | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Alkis, N; Benekli, M; Berk, V; Bilici, A; Colak, D; Coskun, U; Dane, F; Dikilitas, M; Gumus, M; Kaplan, MA; Ozdemir, NY; Ozkan, M | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN | 1 |
| Arning, M; Coleman, R; Helsing, M; Kaufmann, M; Ohnmacht, U; Possinger, K; Stuart, NS | 1 |
| Arends, J; Unger, C | 1 |
| Cuvier, C; Diéras, V; Espié, M; Ferrero, JM; Fumoleau, P; Kalla, S; Kayitalire, L; Llombart-Cussac, A; Namer, M; Perrocheau, G; Ponzio, A; Pouillart, P; Spielmann, M | 1 |
3 review(s) available for gemcitabine and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
[Pancreatic carcinoma (ductal adenocarcinoma)].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal, Breast; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Radiography, Abdominal; Tomography, X-Ray Computed | 2005 |
13 trial(s) available for gemcitabine and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
[Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2007 |
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Quality of Life; Treatment Outcome | 1999 |
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Safety; Vomiting | 2001 |
16 other study(ies) available for gemcitabine and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Gemcitabine; Humans; Ischemia; Middle Aged | 2022 |
Gemcitabine-Induced Retinopathy.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorescein Angiography; Gemcitabine; Humans; Intravitreal Injections; Middle Aged; Neoplasm Staging; Retinal Diseases; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vision Disorders | 2017 |
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Maintenance Chemotherapy; Resorcinols; Treatment Outcome | 2018 |
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2013 |
[A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Receptor, ErbB-2; Trastuzumab | 2013 |
Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Cell Cycle; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; MCF-7 Cells; MicroRNAs; Proportional Hazards Models; RNA Interference | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
Expression of XB130 in human ductal breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Risk Factors; RNA Interference; Signal Transduction; Time Factors; Transfection; Treatment Outcome; Up-Regulation | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mastectomy; Middle Aged; Obesity; Paclitaxel; Skin Ulcer | 2011 |
Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Salvage Therapy; Thrombotic Microangiopathies | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Off-Label Use; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Taxoids; Thrombocytopenia | 2012 |
Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms | 2001 |